CAMP
CAMP4 Therapeutics Corporation
NASDAQ · Healthcare · Biotechnology · US
$4.41
−1.78%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
Market Cap
$276.74M
MomentumView details →
1D Return
−1.78%
YTD Return
−26.74%
RSI (14)
55.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
Market Cap
$276.74M
RSI (14)
55.1
MomentumView details →
1D Return
−1.78%
YTD Return
−26.74%
SummaryUpdated Jun 1, 2026
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) is a biotechnology company founded in 2015 by renowned scientists Richard A. Young and Leonard Zon, headquartered in Cambridge, Massachusetts. The company went public in October 2024 through an initial public offering. CAMP4 operates as a clinical-stage biotechnology company focused on discovering and developing novel treatment options for patients with serious diseases through its proprietary regulatory RNA platform technology.
Similar companies
Latest newsMore news →
CAMP4 Therapeutics Corporation reported a Q2 2026 loss of $0.22 per share, beating the Zacks Consensus Estimate of a $0.24 loss and improving from a $0.62 loss a year earlier.22d agoCAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 clinical trial of CMP-002, an experimental ASO therapy for SYNGAP1-related disorders, in children aged 2 to 18.29d agoCAMP4 Therapeutics announced the second closing of a $100 million private placement, with proceeds of $50.1 million to support advancement of CMP-002 for SYNGAP1-related disorder.32d ago